KEGG ID: 02010
KEGG Diagram for ABC transporters - General
There are 28 IPI Records from this pathway found in Rattus norvegicus.
Location of ABC transporters - General proteins on Rat Genome
| IPI Record | Position |
|---|---|
| 1: Abca1 | 5:70493552-70598070 |
| 2: Abca12_predicted | 9:70328330-70501128 |
| 3: Abca2 | 3:3595423-3615328 |
| 4: Abca5 | 10:99724778-99793593 |
| 5: Abca7 | 7:11203983-11222960 |
| 6: Abcb11 | :- |
| 7: Abcb1a | 4:21709855-21796643 |
| 8: Abcb1b | 4:21829422-21912527 |
| 9: Abcb4 | 4:21946113-22147328 |
| 10: Abcb6 | 9:74454806-74463099 |
| 11: Abcb7 | X:92280212-92430414 |
| 12: Abcb9 | 12:33623383-33656242 |
| 13: Abcc1 | 10:450822-575705 |
| 14: Abcc2 | :- |
| 15: Abcc3 | 10:82987107-83030751 |
| 16: Abcc5 | 11:82714334-82809354 |
| 17: Abcc6 | 1:96448588-96524655 |
| 18: Abcc8 | 1:96622502-96703723 |
| 19: Abcc9 | 4:180526458-180576553 |
| 20: Abcd2 | 7:129542756-129591363 |
| 21: Abcd3 | 2:218396067-218564738 |
| 22: Abcg1 | 20:9390485-9459574 |
| 23: Abcg2 | 4:87502594-87560368 |
| 24: Abcg5 | 6:8027647-8064425 |
| 25: Abcg8 | 6:8064741-8080571 |
| 26: Cftr | 4:43909789-44040151 |
| 27: Tap1 | 20:4790363-4800997 |
| 28: Tap2 | 20:4770446-4784488 |
There are 28 IPI Records from this pathway found in Mus musculus.
Location of ABC transporters - General proteins on Mouse Genome
| IPI Record | Position |
|---|---|
| 1: Abca1 | 4:53051888-53180992 |
| 2: Abca2 | 2:25250712-25270549 |
| 3: Abca3 | 17:24139627-24141224 |
| 4: Abca4 | 3:122036482-122172083 |
| 5: Abca5 | 11:110085459-110153768 |
| 6: Abca6 | 11:109992910-110067818 |
| 7: Abca7 | 10:79400744-79418701 |
| 8: Abca8a | 11:109841726-109907710 |
| 9: Abca8b | 11:109750357-109811906 |
| 10: Abca9 | 11:109916912-109984243 |
| 11: Abcb10 | 8:126838549-126869212 |
| 12: Abcb11 | 2:69039121-69143453 |
| 13: Abcb1a | 5:8666098-8754140 |
| 14: Abcb1b | 5:8804192-8872314 |
| 15: Abcb4 | 5:8899723-8965232 |
| 16: Abcb6 | 1:75054785-75063430 |
| 17: Abcb7 | X:100486163-100616553 |
| 18: Abcb8 | 5:23904220-23920116 |
| 19: Abcb9 | 5:124322151-124356393 |
| 20: Abcc1 | 16:14275138-14388453 |
| 21: Abcc10 | 17:45766762-45791226 |
| 22: Abcc12 | 8:89394946-89456695 |
| 23: Abcc2 | 19:43835715-43891262 |
| 24: Abcc3 | 11:94159385-94209066 |
| 25: Abcc5 | 16:20244846-20339937 |
| 26: Abcc6 | 7:45844422-45898328 |
| 27: Abcc9 | 6:142546356-142659537 |
| 28: Abcd1 | X:69969429-69991252 |
| 29: Abcd2 | 15:90973638-91019574 |
| 30: Abcd3 | 3:121750933-121807238 |
| 31: Abcd4 | 12:85492281-85507118 |
| 32: Abcg1 | 17:30784710-30842784 |
| 33: Abcg2 | 6:58526249-58622028 |
| 34: Abcg3 | 5:105175359-105223019 |
| 35: Abcg4 | 9:44024185-44039239 |
| 36: Abcg5 | 17:84566560-84591337 |
| 37: Abcg8 | 17:84591457-84608659 |
| 38: Cftr | 6:18120687-18272767 |
| 39: Tap1 | 17:33798022-33807437 |
| 40: Tap2 | 17:33814426-33826594 |
There are 28 IPI Records from this pathway found in Homo sapiens.
Location of ABC transporters - General proteins on Human Genome
| IPI Record | Position |
|---|---|
| 1: ABCA1 | 9:106583104-106730339 |
| 2: ABCA10 | 17:64655772-64752582 |
| 3: ABCA12 | 2:215504522-215711396 |
| 4: ABCA13 | 7:48208389-48657637 |
| 5: ABCA3 | 16:2265886-2330748 |
| 6: ABCA4 | 1:94230981-94359279 |
| 7: ABCA5 | 17:64754387-64834885 |
| 8: ABCA6 | 17:64586442-64649610 |
| 9: ABCA7 | 19:992361-1016424 |
| 10: ABCA8 | 17:64375028-64463128 |
| 11: ABCA9 | 17:64482580-64568731 |
| 12: ABCB1 | 7:86970884-87180500 |
| 13: ABCB10 | 1:227718952-227761065 |
| 14: ABCB11 | 2:169487694-169596079 |
| 15: ABCB4 | 7:86869302-86942991 |
| 16: ABCB5 | 7:20653518-20761772 |
| 17: ABCB6 | 2:219782738-219791917 |
| 18: ABCB7 | X:74189834-74292857 |
| 19: ABCB8 | 7:150356443-150380773 |
| 20: ABCC1 | 16:16009174-16142883 |
| 21: ABCC10 | 6:43503270-43526142 |
| 22: ABCC11 | 16:46758442-46838806 |
| 23: ABCC12 | 16:46674385-46738182 |
| 24: ABCC2 | 10:101532479-101601939 |
| 25: ABCC3 | 17:46067227-46124061 |
| 26: ABCC4 | 13:94470090-94751684 |
| 27: ABCC5 | 3:185120420-185218421 |
| 28: ABCC6 | 16:16151491-16224815 |
| 29: ABCC8 | 11:17371009-17455025 |
| 30: ABCC9 | 12:21845245-21985434 |
| 31: ABCD1 | X:152643517-152663410 |
| 32: ABCD2 | 12:38232814-38300237 |
| 33: ABCD3 | 1:94656584-94756807 |
| 34: ABCD4 | 14:73821902-73839448 |
| 35: ABCG1 | 21:42509335-42590421 |
| 36: ABCG2 | 4:89230441-89299035 |
| 37: ABCG4 | 11:118524960-118538582 |
| 38: ABCG5 | 2:43893115-43919462 |
| 39: ABCG8 | 2:43919607-43959109 |
| 40: CFTR | 7:116907253-117095951 |
| 41: TAP1 | 6:32882385-32891153 |
| 42: TAP2 | 6:32859010-32875945 |
J Hum Genet. 2008 Jun 26;
Chen ZC, Shin SJ, Kuo KK, Lin KD, Yu ML, Hsiao PJ
The absorption efficiency of cholesterol is closely correlated to dietary phytosterol content and determined by genetic factors. The ATP-binding cassette (ABC) transporters ABCG5 and ABCG8 act as a sterol efflux pump to regulate the absorption of cholesterol and phytosterol. The levels of cholesterol and phytosterol associated with a Chinese diet are very different from those associated with a Western diet. This study aims to explore the association between serum total cholesterol/LDL-C levels and ABCG5/ABCG8 polymorphisms in a Taiwanese population consuming an ordinary Chinese diet. A total of 1,046 subjects (894 men and 152 women) were recruited in a hospital-based health check-up center in Kaohsiung Medical University Hospital. Five nonsynonymous polymorphisms of Q604E (ABCG5), D19H, C54Y, T400 K and A632 V (ABCG8) were analyzed by TaqMan genotyping assay. Analysis showed that the D19H polymorphism of the ABCG8 gene was significantly associated with serum total cholesterol, LDL-C levels and HOMA-IR index. Adjusting for sex and age, subjects with the D19H (GC) genotype were significantly associated with a threefold higher risk of high cholesterol and LDL-C levels than subjects with D19 (GG). These results suggest that the D19H polymorphism of ABCG8 could be considered a susceptible gene marker indicating an increased likelihood of developing high cholesterol and LDL-C levels in Taiwanese consuming an ordinary Chinese diet. It is supposed that the coexistence of higher insulin resistance and hypercholesterolemia for carriers of the D19H polymorphism may result in a greater risk of cardiovascular disease.
JAMA. 2008 Jun 4; 299(21): 2524-32
Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A
CONTEXT: Low levels of high-density lipoprotein (HDL) cholesterol are inversely related to cardiovascular risk. Whether this is a causal effect is unclear. OBJECTIVE: To determine whether genetically reduced HDL cholesterol due to heterozygosity for 4 loss-of-function mutations in ABCA1 cause increased risk of ischemic heart disease (IHD). DESIGN, SETTING, AND PARTICIPANTS: Three studies of white individuals from Copenhagen, Denmark, were used: the Copenhagen City Heart Study (CCHS), a 31-year prospective General population study (n = 9022; 28 heterozygotes); the Copenhagen General Population Study (CGPS), a cross-sectional General population study (n = 31,241; 76 heterozygotes); and the Copenhagen Ischemic Heart Disease Study (CIHDS), a case-control study (n = 16,623; 44 heterozygotes). End points in all 3 studies were recorded during the period of January 1, 1976, through July 9, 2007. MAIN OUTCOME MEASURES: Levels of HDL cholesterol in the General population, cellular cholesterol efflux, and the association between IHD and HDL cholesterol and genotype. RESULTS: Heterozygotes vs noncarriers for 4 ABCA1 mutations (P1065S, G1216V, N1800H, R2144X) had HDL cholesterol levels of 41 mg/dL (interquartile range, 31-50 mg/dL) vs 58 mg/dL (interquartile range, 46-73 mg/dL), corresponding to a reduction in HDL cholesterol of 17 mg/dL (P < .001). A 17-mg/dL lower HDL cholesterol level in the CCHS was associated with a multifactorially adjusted hazard ratio for IHD of 1.70 (95% confidence interval [CI], 1.57-1.85). However, for IHD in heterozygotes vs noncarriers, the multifactorially adjusted hazard ratio was 0.67 (95% CI, 0.28-1.61; 1741 IHD events) in the CCHS, the multifactorially adjusted odds ratio was 0.82 (95% CI, 0.34-1.96; 2427 IHD events) in the CGPS, and the multifactorially adjusted odds ratio was 0.86 (95% CI, 0.32-2.32; 2498 IHD cases) in the CIHDS. The corresponding odds ratio for IHD in heterozygotes vs noncarriers for the combined studies (n = 41,961; 6666 cases; 109 heterozygotes) was 0.93 (95% CI, 0.53-1.62). CONCLUSION: Lower plasma levels of HDL cholesterol due to heterozygosity for loss-of-function mutations in ABCA1 were not associated with an increased risk of IHD.
Med Chem. 2008 May; 4(3): 194-205
Carta A, Piras S, Paglietti G, Pricl S, La Colla P, Busonera B, Loddo R
A series of quinoxalines variously substituted, namely 3-arylthiomethyl-1,6-dimethylquinoxalin-2-ones (6a-f), 3-arylthiomethyl-1-benzyl-7-trifluoromethylquinoxalin-2-ones (8a-g) and 2-arylthiomethyl-3-benzyloxy-6-trifluoro-methylquinoxalines (10a,b,e-h), were synthesized and compared with previous arylphenoxymethylquinoxalines (1a-f, 2a-f and 3a-b). The purpose was to verify whether the replacement of oxygen with sulphur atom and the insertion of different substituents on the phenyl side chain were able to improve the capability to inhibit the Pgp pump and restore the antiproliferative activity of clinically useful drugs, such as doxorubicin (Doxo), vincristine (VCR) and etoposide (VP16), in drug-resistant human nasopharyngeal carcinoma KB cells (KB(wt), KB(MDR), KB(7D) and KB(V20C)). Furthermore, 2,3-bis(aryloxy-methyl)-6-trifluoromethylquinoxalines (13a-c) were designed with the objective to evaluate the capability of the double side chain to potentiate the antiproliferative activity of the drugs tested. Biological assays showed that title compounds were, in General, endowed with good activity as Pgp inhibitors. In particular compound 3a, bearing 2-CONHPh substituent on phenoxymethyl side chain, resulted the most effective, while the double side chain (compound 13c) gives the ability to inhibit a different MRP pump (a membrane glycoprotein named mrp). Furthermore, we can conclude that replacement of oxygen with sulphur atom did not improve the biological activity.
Drug Discov Today. 2008 May; 13(9-10): 379-93
Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B
ATP binding cassette (ABC) drug transporters play an important role in cancer drug resistance, protection against xenobiotics, and in General in the passage of drugs through cellular and tissue barriers. This review explores how human ABC transporters modulate the pharmacological effects of various drugs, and how this predictable ADME-TOX modulation can be used during the process of drug discovery and development. We provide a description of the relevant human ABC drug transporters and review the models and assay systems that can be applied for the analysis of their expected drug interactions. The use of the in vitro, in vivo, in silico models, their combination, and the emerging clinical information are evaluated with respect to their potential application in early drug screening.
J Med Chem. 2008 Jun 12; 51(11): 3275-87
Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P
The chemical space of registered oral drugs was explored for inhibitors of the human multidrug-resistance associated protein 2 (MRP2; ABCC2), using a data set of 191 structurally diverse drugs and drug-like compounds. The data set included a new reference set of 75 compounds, for studies of hepatic drug interactions with transport proteins, CYP enzymes, and compounds associated with liver toxicity. The inhibition of MRP2-mediated transport of estradiol-17beta-D-glucuronide was studied in inverted membrane vesicles from Sf9 cells overexpressing human MRP2. A total of 27 previously unknown MRP2 inhibitors were identified, and the results indicate an overlapping but narrower inhibitor space for MRP2 compared with the two other major ABC efflux transporters P-gp (ABCB1) and BCRP (ABCG2). In addition, 13 compounds were shown to stimulate the transport of estradiol-17beta-D-glucuronide. The experimental results were used to develop a computational model able to discriminate inhibitors from noninhibitors according to their molecular structure, resulting in a predictive power of 86% for the training set and 72% for the test set. The inhibitors were in General larger and more lipophilic and presented a higher aromaticity than the noninhibitors. The developed computational model is applicable in an early stage of the drug discovery process and is proposed as a tool for prediction of MRP2-mediated hepatic drug interactions and toxicity.
Biochemistry. 2008 May 27; 47(21): 5699-708
Procko E, Gaudet R
The transporter associated with antigen processing (TAP), an ABC transporter, pumps cytosolic peptides into the endoplasmic reticulum, where the peptides are loaded onto class I MHC molecules for presentation to the immune system. Transport is fueled by the binding of ATP to two cytosolic nucleotide-binding domains (NBDs) and ATP hydrolysis. We demonstrate biochemically that there are two electrostatic interactions across the interface between the two TAP NBDs and that these interactions are important for peptide transport. Notably, disrupting these interactions by mutagenesis does not greatly alter the ATP hydrolysis rate in an isolated NBD model system, suggesting that the interactions function at alternative stages in the transport cycle. The data support the General model for ABC transporters in which the NBDs form a tight, closed conformation during transport. Our results are discussed in relation to other ABC transporters that do or do not conserve potential interacting residues of opposite charges at the homologous positions.
Bacitracin sensing in Bacillus subtilis.
Mol Microbiol. 2008 May; 68(3): 768-85
Rietkötter E, Hoyer D, Mascher T
The extracellular presence of antibiotics is a common threat in microbial life. Their sensitive detection and subsequent induction of appropriate resistance mechanisms is therefore a prerequisite for survival. The bacitracin stress response network of Bacillus subtilis consists of four signal-transducing systems, the two-component systems (TCS) BceRS, YvcPQ and LiaRS, and the extracytoplasmic function (ECF) sigma factor sigma(M). Here, we investigated the mechanism of bacitracin perception and the response hierarchy within this network. The BceRS-BceAB TCS/ABC transporter module is the most sensitive and efficient bacitracin resistance determinant. The ABC transporter BceAB not only acts as a bacitracin detoxification pump, but is also crucial for bacitracin sensing, indicative of a novel mechanism of stimulus perception, conserved in Firmicutes bacteria. The Bce system seems to respond to bacitracin directly (drug sensing), whereas the LiaRS TCS and sigma(M) respond only at higher concentrations and indirectly to bacitracin action (damage sensing). The YvcPQ-YvcRS system is subject to cross-activation via the paralogous Bce system, and is therefore only indirectly induced by bacitracin. The bacitracin stress response network is optimized to respond to antibiotic gradients in a way that maximizes the gain and minimizes the costs of this stress response.
Drug Metab Dispos. 2008 Jul; 36(7): 1249-54
MacLean C, Moenning U, Reichel A, Fricker G
Intestinal ATP binding cassette (ABC) transporters may affect the bioavailability and effectiveness of orally administered drugs. Available studies on regional expression of intestinal efflux transporters were done with selected intestinal segments only and inconsistent with regard to the variability of transporter expression and the course of expression along the intestine. For an evaluation of the consistency between mRNA and protein expression, relative expression levels of P-glycoprotein (Pgp; ABCB1), breast cancer resistance protein (Bcrp; ABCG2), and multidrug resistance-associated protein (Mrp) 2 (ABCC2) were determined using quantitative real-time-polymerase chain reaction and Western blot in rat intestinal segments from duodenum, jejunum, ileum, and colon. In addition, the protein expression of Pgp, Bcrp, and Mrp2 from the entire rat intestine was studied by a complete 3-cm segmentation to evaluate the predictive power of expression analyses from selected intestinal segments. Pgp showed an increase from proximal to distal regions, Bcrp showed an arcuate pattern with highest expression toward the end of small intestine, and Mrp2 decreased along the intestinal axis from proximal to distal parts. No gender specific differences could be observed. Regarding the concordance of mRNA and protein expression, Pgp and Bcrp mRNA samples allow good estimations about the corresponding protein expression (for Pgp limited to the mdr1a isoform), but for Mrp2, pronounced deviation could be observed. All transporters showed considerable intra- and interindividual variability, especially at the protein level, making it problematic to take transporter expressions of small sections exemplary for General assumptions on intestinal abundances.
Mol Vis. 2008; 14: 262-7
Riveiro-Alvarez R, Vallespin E, Wilke R, Garcia-Sandoval B, Cantalapiedra D, Aguirre-Lamban J, Avila-Fernandez A, Gimenez A, Trujillo-Tiebas MJ, Ayuso C
PURPOSE: Stargardt disease (STGD), characterized by central visual impairment, is the most common juvenile macular dystrophy. All recessively inherited cases are thought to be due to mutations in the ABCA4 gene. Early-onset autosomal recessive retinitis pigmentosa (arRP) is a severe retinal degeneration that presents before the patient is ten years old. It has been associated with mutations in different genes, including CRB1. The aim of this study was to determine the genetic causes for two different retinal dystrophies, STGD and early-onset arRP, both segregating in one Spanish family. METHODS: Mutational analyses were performed using the ABCR400 and Leber congenital amaurosis (LCA) genotyping microarrays. Additional scanning for mutations was conducted by denaturing high performance liquid chromatography (dHPLC); results were confirmed by direct sequencing. RESULTS: A patient, who exhibited a STGD phenotype, was found to be homozygous for the p.Asn1805Asp (c.5413A>G) mutation in ABCA4. However, his affected sister, who had the arRP phenotype, was found to be heterozygous for this allele; no other sequence change could be found in ABCA4. Analysis using the LCA chip revealed the p.Cys948Tyr mutation in CRB1 in heterozygous state. A second mutation (p.Trp822ter) was found in the CRB1 gene in the affected female by denaturing high performance liquid chromatography (dHPLC) and direct sequencing. CONCLUSIONS: Two distinct retinal dystrophies with mutations affecting two different genes cosegregated in this family. The presence of two different phenotypes associated with mutations in two distinct genes in one single family must be considered especially when dealing with retinal dystrophies which bear high carrier frequencies in General population.
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.
Pharmacogenet Genomics. 2008 Apr; 18(4): 299-305
Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, Molokhia M, Hofman A, Uitterlinden AG, Stricker BH
BACKGROUND AND OBJECTIVE: Digoxin is a known substrate of ATP-binding cassette B1 (ABCB1/MDR1). The results of studies on the association between ABCB1 polymorphisms and digoxin kinetics, however, remain contradictory. Almost all studies were small and involved only single dose kinetics. The goal of this study was to establish ABCB1 genotype effect on digoxin blood concentrations in a large cohort of chronic digoxin users in a General Dutch European population. METHODS: Digoxin users were identified in the Rotterdam Study, a prospective population-based cohort study of individuals aged 55 years and above. Digoxin blood levels were gathered from regional hospitals and laboratories. ABCB1 single nucleotide polymorphisms (SNPs) 1236C-->T, 2677G-->T/A, and 3435C-->T were assessed on peripheral blood DNA using Taqman assays. We studied the association between the ABCB1 genotypes and haplotypes, and digoxin blood levels using linear regression models adjusting for potential confounders. RESULTS: Digoxin serum levels and DNA were available for 195 participants (56.4% women, mean age 79.4 years). All three ABCB1 variants were significantly associated with serum digoxin concentration (0.18-0.21 microg/l per additional T allele). The association was even stronger for the 1236-2677-3435 TTT haplotype allele [0.26 mug/l (95% CI 0.14-0.38)], but absent for other haplotypes (CGC allele considered referent), suggesting an interaction of SNPs in a causal haplotype instead of individual SNP effects. CONCLUSION: We found that the common ABCB1 1236C-->T, 2677G-->T, and 3435C-->T variants and the associated TTT haplotype were associated with higher digoxin serum concentrations in a cohort of elderly European digoxin users in the General population.
Rice yellow mottle virus stress responsive genes from susceptible and tolerant rice genotypes.
BMC Plant Biol. 2008; 8: 26
Ventelon-Debout M, Tranchant-Dubreuil C, Nguyen TT, Bangratz M, Siré C, Delseny M, Brugidou C
BACKGROUND: The effects of viral infection involve concomitant plant gene variations and cellular changes. A simple system is required to assess the complexity of host responses to viral infection. The genome of the Rice yellow mottle virus (RYMV) is a single-stranded RNA with a simple organisation. It is the most well-known monocotyledon virus model. Several studies on its biology, structure and phylogeography have provided a suitable background for further genetic studies. 12 rice chromosome sequences are now available and provide strong support for genomic studies, particularly physical mapping and gene identification. RESULTS: The present data, obtained through the cDNA-AFLP technique, demonstrate differential responses to RYMV of two different rice cultivars, i.e. susceptible IR64 (Oryza sativa indica), and partially resistant Azucena (O. s. japonica). This RNA profiling provides a new original dataset that will enable us to gain greater insight into the RYMV/rice interaction and the specificity of the host response. Using the SIM4 subroutine, we took the intron/exon structure of the gene into account and mapped 281 RYMV stress responsive (RSR) transcripts on 12 rice chromosomes corresponding to 234 RSR genes. We also mapped previously identified deregulated proteins and genes involved in partial resistance and thus constructed the first global physical map of the RYMV/rice interaction. RSR transcripts on rice chromosomes 4 and 10 were found to be not randomly distributed. Seven genes were identified in the susceptible and partially resistant cultivars, and transcripts were colocalized for these seven genes in both cultivars. During virus infection, many concomitant plant gene expression changes may be associated with host changes caused by the infection process, General stress or defence responses. We noted that some genes (e.g. ABC transporters) were regulated throughout the kinetics of infection and differentiated susceptible and partially resistant hosts. CONCLUSION: We enhanced the first RYMV/rice interaction map by combining information from the present study and previous studies on proteins and ESTs regulated during RYMV infection, thus providing a more comprehensive view on genes related to plant responses. This combined map provides a new tool for exploring molecular mechanisms underlying the RYMV/rice interaction.
Rifampicin induces MDR1 expression in Candida albicans.
J Antimicrob Chemother. 2008 Mar; 61(3): 541-7
Vogel M, Hartmann T, Köberle M, Treiber M, Autenrieth IB, Schumacher UK
OBJECTIVES: Overexpression of efflux pumps such as MDR1 has been identified as an important mechanism contributing to fluconazole resistance in Candida albicans. This phenomenon is frequently observed in fluconazole-resistant strains isolated from AIDS patients treated with various pharmaceuticals. Therefore, we hypothesized that some of these compounds might influence the expression of genes responsible for fluconazole resistance. METHODS: We examined a variety of clinically relevant compounds for their in vitro effects on MDR1 expression with a C. albicans reporter strain containing a transcriptional fusion of the MDR1 promoter (MDR1P) with the gfp gene. Activation of the MDR1 promoter and subsequent green fluorescent protein production was determined by fluorescence microscopy and flow cytometry. Additionally, MDR1 transcription was confirmed and quantified by RT-PCR analysis, followed by Mdr1p detection by western blot. Finally, the effect of a selected agent on resistance to fluconazole was tested by chequerboard titration of both substances. RESULTS: Of 15 compounds tested, only rifampicin induced a rapid and dose-dependent increase in MDR1 expression (up to 122-fold induction), whereas structurally related molecules such as rifabutin and rifamycin were not active. Induction of MDR1 expression upon rifampicin exposure was also observed in 10 blood culture isolates. In contrast, rifampicin exposure did not markedly affect the expression of the transporters CDR1 and CDR2. Increased MDR1 expression was accompanied by elevated MICs for fluconazole after exposure of C. albicans to rifampicin, whereas Mdr1p expression was only moderately induced. CONCLUSIONS: Out of the compounds examined, only rifampicin specifically induced MDR1 expression in all C. albicans strains tested. Rifampicin may play a General role in signal transduction or another means of modulation of gene expression in C. albicans.
Transplantation. 2008 Jan 27; 85(2): 179-84
Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, Pfeffer P, Hartmann A, Midtvedt K
BACKGROUND: We investigated cyclosporine A (CsA) concentrations at the site of action, inside T-lymphocytes, to evaluate its applicability as a new supplementary therapeutic drug monitoring method after renal transplantation. METHOD: In this prospective single-center study, 20 kidney transplant recipients, mean age 54 (range 21-74) years, on CsA-based immunosuppression were included within 2 weeks posttransplant and followed for 3 months. Nine patients also had one full 12-hour pharmacokinetic profile performed. T-lymphocytes were isolated from 7 ml whole blood using Prepacyte and intracellular CsA concentrations were determined using a validated liquid chromatography double mass spectrometry method. RESULTS: Seven patients (35%) experienced acute rejections (all biopsy verified) during the first three months posttransplantation. Intracellular CsA concentrations tended to decline 1 week prior to acute rejection and the decrease was significant (-27.1+/-14.6%, P=0.014) three days before the rejection episodes were recognized clinically. In addition, the intracellular CsA area under the curve 0-12 measured during stable phase was 182% higher in the rejection-free patients (P=0.004). There was no difference between patients experiencing rejection and the rejection-free patients with respect to CsA C2-levels, dose (mg/kg), human leukocyte antigen mismatch, donor age, recipient age, or ABCB1 genotyping. CONCLUSION: Intracellular CsA T-lymphocyte concentrations declined significantly 3 days prior to a rejection episode and there was a General lower intracellular exposure of CsA in recipients experiencing rejection. Intracellular measurement of CsA therefore seems to have a potential to further improve individualization of therapeutic drug monitoring. Larger studies are needed to elucidate the role for intracellular T-lymphocyte measurements in ordinary clinical care, for both CsA and other immunosuppressive drugs.
Biophys J. 2008 May 15; 94(10): 3956-65
Doeven MK, van den Bogaart G, Krasnikov V, Poolman B
The oligopeptide transporter Opp is a five-component ABC uptake system. The extracytoplasmic lipid-anchored substrate-binding protein (or receptor) OppA delivers peptides to an integral membrane complex OppBCDF (or translocator), where, on ATP binding and hydrolysis, translocation across the membrane takes place. OppA and OppBCDF were labeled with fluorescent probes, reconstituted into giant unilamellar vesicles, and the receptor-translocator interactions were investigated by fluorescence correlation spectroscopy. Lateral mobility of OppA was reduced on incorporation of OppBCDF into giant unilamellar vesicles, and decreased even further on the addition of peptide. Fluorescence cross-correlation measurements revealed that OppBCDF distinguished liganded from unliganded OppA, binding only the former. Addition of ATP or its nonhydrolyzable analog AMP-PNP resulted in release of OppA from OppBCDF. In vanadate-trapped "transition state" conditions, OppA also was not bound by OppBCDF. A model is presented in which ATP-binding to OppDF results in donation of peptide to OppBC and simultaneous release of OppA. ATP-hydrolysis would complete the peptide translocation and reset the transporter for another catalytic cycle. Implications in terms of a General transport mechanism for ABC importers and exporters are discussed.
Curr Med Res Opin. 2008 Feb; 24(2): 591-9
Robertson SM, Davey RT, Voell J, Formentini E, Alfaro RM, Penzak SR
OBJECTIVE: Animal and in vitro data suggest that Ginkgo biloba extract (GBE) may modulate CYP3A4 activity. As such, GBE may alter the exposure of HIV protease inhibitors metabolized by CYP3A4. It is also possible that GBE could alter protease inhibitor pharmacokinetics (PK) secondary to modulation of P-glycoprotein (P-gp). The primary objective of the study was to evaluate the effect of GBE on the exposure of lopinavir in healthy volunteers administered lopinavir/ritonavir. Secondary objectives were to compare ritonavir exposure pre- and post-GBE, and assess the effect of GBE on single doses of probe drugs midazolam and fexofenadine. METHODS: This open-label study evaluated the effect of 2 weeks of standardized GBE administration on the steady-state exposure of lopinavir and ritonavir in 14 healthy volunteers administered lopinavir/ritonavir to steady-state. In addition, single oral doses of probe drugs midazolam and fexofenadine were administered prior to and after 4 weeks of GBE (following washout of lopinavir/ritonavir) to assess the influence of GBE on CYP3A and P-gp activity, respectively. RESULTS: Lopinavir, ritonavir and fexofenadine exposures were not significantly affected by GBE administration. However, GBE decreased midazolam AUC(0-infinity) and C(max) by 34% (p = 0.03) and 31% (p = 0.03), respectively, relative to baseline. In General, lopinavir/ritonavir and GBE were well tolerated. Abnormal laboratory results included mild elevations in hepatic enzymes, cholesterol and triglycerides, and mild-to-moderate increases in total bilirubin. CONCLUSIONS: Our results suggest that GBE induces CYP3A metabolism, as assessed by a decrease in midazolam concentrations. However, there was no change in the exposure of lopinavir, likely due to ritonavir's potent inhibition of CYP3A4. Thus, GBE appears unlikely to reduce the exposure of ritonavir-boosted protease inhibitors, while concentrations of unboosted protease inhibitors may be affected. Limitations to our study include the single sequence design and the evaluation of a ritonavir-boosted protease inhibitor exclusively.
[Multidrug resistance in chronic lymphocytic leukemia]
Orv Hetil. 2008 Jan 27; 149(4): 161-7
Szendrei T, Magyarlaki T, Kovács G, Nagy A, Szomor A, Molnár L, Dávid M, Tokés-Füzesi M, Rideg O, Pótó L, Pajor L, Kajtár B, Losonczy H
INTRODUCTION: New prognostic factors discovered in chronic lymphocytic leukemia have recently got into the center of clinical interest. While the predictive value of cytogenetical abnormalities, immunoglobulin heavy chain gene mutation status, CD38 and ZAP70 expression is already well known, the significance of multi-drug resistance in chronic lymphocytic leukemia is not well characterized. AIMS: The goal of this study was to characterize the multidrug resistance features in 82 patients with chronic lymphocytic leukemia at the genetical, expression- and functional level and to compare it with the patient's clinical behavior (survival and response to therapy). METHODS: Light Cycler Real Time PCR based "Single Nucleotide Polymorphism" analysis of the MDR1 gene, as a biological predictor of the expression level of P-glycoprotein was tested in 66 patients with chronic lymphocytic leukemia. P-glycoprotein expression and MDR-function was detected in 82 cases by flow cytometry (by use of anti-P-glycoprotein monoclonal antibody and calcein-verapamil functional test). Response to therapy was analyzed by statistical Fisher-test in the treated 35 patients. The survival analysis (Log-rank test) was performed on the whole population ( n = 82). RESULTS: No significant correlation was found between the three levels of multidrug resistance (genetics, phenotype, function) in our patients with chronic lymphocytic leukemia. P-glycoprotein positive cases (n = 9) were predominantly non-responders (8/9, 89%). There must be, however, other mechanisms causing non-response (total non-responders: 13/35 treated cases). Most of P-glycoprotein negative CLL patients (n = 26) responded well (21/26, 80%) to chemotherapy (responders: 22/35 treated CLL) (p < 0,001). The tendency was the same in the average expected survival rate between P-glycoprotein positive and negative patients (84 vs 203 months) but the difference was not significant (p = 0,106). CONCLUSIONS: This study proved the clinical prognostic significance of P-glycoprotein expression of leukaemic cells predicting the chemotherapy response and partially estimating the General survival of patients suffering from chronic lymphocytic leukemia.
Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity.
Mol Pharm. 2008 Jan-Feb; 5(1): 77-91
Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL
Obesity and type II diabetes pose a serious human health risk. Obese or diabetic patients usually take prescription drugs that require hepatic and renal metabolism and transport, and these patients sometimes display different pharmacokinetics of these drugs. Therefore, mRNA and protein expression of drug-metabolizing enzymes (DMEs) and transporters was measured in livers and kidneys of adult wild-type and ob/ob mice, which model obesity and diabetes. mRNA expression of numerous DMEs increased by at least 2-fold in livers of male ob/ob mice, including Cyp4a14, Cyp2b10, NAD(P)H:quinone oxidoreductase 1 (Nqo1), and sulfotransferase 2a1/2. In General, expression of uptake transporters was decreased in livers of ob/ob mice, namely organic anion-transporting polypeptides (Oatps) and sodium/taurocholate cotransporting polypeptide (Ntcp). In particular, Oatp1a1 mRNA and protein expression in livers of ob/ob mice was diminished to <5% and <15% of that in wild-types, respectively. Generally, the mRNA and protein expression of efflux transporters multidrug resistance-associated proteins (Mrps) was increased in livers of ob/ob mice, particularly with Mrp4 expression being elevated by at least 6-fold and Mrp2 expression at least 3-fold in livers of ob/ob mice. In kidney, Nqo1, Mrp3, 4, Oatp1a1, and organic anion transporter 2 (Oat2) showed significant alterations with mRNA expression levels in ob/ob mice, being increased for Nqo1 and Mrp4 and decreased for Mrp3, Oatp1a1, and Oat2. In summary, the expression of a number of DMEs and transporters was significantly altered in livers and kidneys of ob/ob mice. Since expression of some DMEs and transporters is regulated similarly between mouse and human, the data from this study suggest that transporter expression in liver and kidney may be changed in patients presenting with obesity and/or type II diabetes.
Hum Mutat. 2008 Jan; 29(1): 205
Vanakker OM, Leroy BP, Coucke P, Bercovitch LG, Uitto J, Viljoen D, Terry SF, Van Acker P, Matthys D, Loeys B, De Paepe A
Pseudoxanthoma elasticum (PXE) is a heritable connective tissue disorder characterized by ocular, cutaneous and cardiovascular manifestations. It is caused by mutations in the ABCC6 gene (chr. 16p13.1), encoding a transmembrane transporter protein, the substrate and biological function of which are currently unknown. A comprehensive clinical and molecular study of 38 Belgian PXE probands and 21 relatives (4 affected and 17 carriers) was performed. An extensive clinical evaluation protocol was implemented with serial fundus, skin and cardiovascular evaluation. We report on 14 novel mutations in the ABCC6 gene. We observed extensive variability in severity of both cutaneous and ocular lesions. The type of skin lesion however usually remained identical throughout the evolution of the disorder, while ophthalmological progression was mainly due to functional decline. Peripheral artery disease (53%) and stroke (15%) were significantly more prevalent than in the General population (10-30% and 0.3-0.5% respectively). Interestingly, we also observed a relatively high incidence of subclinical peripheral artery disease (41%) in our carrier population. We highlight the significance of peripheral artery disease and stroke in PXE patients as well as the subclinical manifestations in carriers. Through follow-up data we gained insight into the natural history of PXE. We propose a cost- and time-efficient two-step method of ABCC6 analysis which can be used in different populations. Additionally, we created a diagnostic flowchart and attempted to define the role of molecular analysis of ABCC6 in the work-up of a PXE patient.
A new subfamily of bacterial glutamate/aspartate receptors.
Biol Chem. 2008 Jan; 389(1): 33-6
Singh B, Röhm KH
The specificity of bacterial nutrient importers of the ATP-binding cassette (ABC) type depends on external receptor proteins that not only bind the solute to be transported, but also initiate the transport process by inducing ATP hydrolysis in the cytoplasmic nucleotide-binding domains. Here we propose a mode of ligand binding to the solute-binding protein AatJ that is required for glutamate uptake by the AatJMQP transporter in Pseudomonas putida KT2440. A homology model of the AatJ-glutamate complex was constructed using the E. coli glutamine-binding protein GlnH as the template. The General validity of the model was then confirmed by alanine scanning mutagenesis of several residues predicted to interact with the ligand and by semi-quantitative binding studies with [(14)C]-Glu and [(14)C]-Asp. A database search indicated that AatJ is a member of a distinct subfamily of the family 3 solute-binding proteins with specificity towards glutamate and aspartate.
J Mol Neurosci. 2008 Feb; 34(2): 121-9
Vavaiya KV, Briski KP
Cellular metabolic stasis is monitored in the lateral hypothalamic area (LHA) and ventromedial hypothalamic nucleus (VMH), the classically defined hypothalamic "anoretic" and "satiety" centers, respectively. Neuronal glucose (GLUT3, GLUT4) and monocarboxylate (MCT2) transporter genes are expressed in both sites, suggesting that glucose and lactate, a product of astrocytic glycolysis, may fuel aerobic respiration in local neurons. Evidence that glucose utilization in the hypothalamus, but not other brain regions, is reported to vary according to cyclic estradiol secretion suggests that this hormone may regulate uptake and/or catabolism of this fuel. We investigated the hypothesis that estradiol exerts site-specific regulatory effects on basal and insulin-induced hypoglycemia (IIH)-associated MCT2 and neuronal glucose transporter mRNA profiles, and expression of genes that encode the substrate sensor, glucokinase (GCK), and the sulfonylurea receptor-1 (SUR) subunit of the energy-dependent potassium channel, K(ATP), in the female rat LHA and VMH. As caudal fourth ventricular (CV4) lactate infusion intensifies hypoglycemia in this gender, we also examined whether demonstrable LHA and VMH gene responses to IIH are correspondingly amplified. MCT2, GLUT3, GLUT4, GCK, and SUR1 mRNA levels in the LHA and VMH did not differ between saline-injected ovariectomized (OVX) rats implanted with estradiol benzoate (EB) or oil (O). LHA: IIH had no impact on gene profiles, excluding SUR1, in EB-treated animals, but decreased these transcripts, with the exception of GCK, in OVX + O rats. CV4 lactate infusion in hypoglycemic OVX + EB animals suppressed each mRNA profile, but reversed IIH-associated reductions in MCT2, GLUT3, and GLUT4 gene expression in OVX + O. VMH: IIH increased MCT2 and GLUT4 transcripts in OVX + EB, but not OVX + O rats and decreased GCK mRNA in both groups. Lactate plus insulin treatment elevated VMH MCT2, GLUT3, SUR1, and GCK gene expression in EB- and O-implanted OVX rats, but augmentation of the former three profiles was greater in the presence of EB. The data show that LHA and VMH neurons exhibited dissimilar, estradiol-dependent adjustments in neuronal lactate and glucose transporter, GCK, and SUR1 gene expression during IIH, and that in the presence of estradiol, caudal hindbrain lactate infusion during IIH elicited divergent changes in MCT2, GLUT3, GCK, and SUR1 gene expression in the LHA and VMH, where these transcripts were, respectively, diminished or augmented. These results support the need to investigate the potential impact of site-specific adjustments in fuel uptake and KATP regulation of membrane voltage on General and specialized, e.g., chemosensory, neuronal functions.